Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation

被引:73
作者
Bellucci, Arianna [1 ]
Collo, Ginetta [1 ]
Sarnico, Ilenia [1 ]
Battistin, Leontino [2 ]
Missale, Cristina [1 ]
Spano, PierFranco [1 ]
机构
[1] Univ Brescia, Dept Biomed Sci & Biotechnol, Div Pharmacol, I-25123 Brescia, Italy
[2] IRCCS S Camillo Hosp, Venice, Italy
关键词
alpha-synuclein; D-2/D-3 receptor agonists; dopamine overload; dopamine transporter; glucose deprivation; Parkinson's disease;
D O I
10.1111/j.1471-4159.2008.05406.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Progressive degeneration and intraneuronal Lewy bodies made of filamentous alpha-synuclein (alpha-syn) in dopaminergic cells of the nigrostriatal system are characteristics of Parkinson's disease (PD). Glucose uptake is reduced in some of the brain regions affected by PD neurodegenerative changes. Defects in mitochondrial activity in the substantia nigra have been observed in the brain of patients affected by PD and substantia nigra lesions can induce the onset of a secondary parkinsonism. Thus, energy starvation and consequently metabolic impairment to dopaminergic neurons may be related to the onset of PD. On this line, we evaluated the effect of nutrient starvation, reproduced 'in vitro' by glucose deprivation (GD), in primary mesecephalic neuronal cultures and dopaminergic-differentiated SH-SY5Y cells, to evaluate if decreased glucose support to dopaminergic cells can lead to mitochondrial damage, neurodegeneration and alpha-syn misfolding. Furthermore, we investigated the effect of dopamine (DA) treatment in the presence of a DA-uptake inhibitor or of the D-2/D-3 receptor (D2R/D3R) agonist quinpirole on GD-treated cells, to evaluate the efficacy of these therapeutic compounds. We found that GD induced the formation of fibrillary aggregated alpha-syn inclusions containing the DA transporter in dopaminergic cells. These alterations were accompanied by dopaminergic cell death and were exacerbated by DA overload. Conversely, the block of DA uptake and D2R/D3R agonist treatment exerted neuroprotective effects. These data indicate that glucose starvation is likely involved in the induction of PD-related pathological changes in dopaminergic neurons. These changes may be counteracted by the block of DA uptake and by dopaminergic agonist treatment.
引用
收藏
页码:560 / 577
页数:18
相关论文
共 42 条
[1]   BRAIN PEROXIDASE AND CATALASE IN PARKINSON DISEASE [J].
AMBANI, LM ;
VANWOERT, MH ;
MURPHY, S .
ARCHIVES OF NEUROLOGY, 1975, 32 (02) :114-118
[2]   Dopamine receptor agonists mediate neuroprotection in malonate-induced striatal lesion in the rat [J].
Armentero, MT ;
Fancellu, R ;
Nappi, G ;
Blandini, F .
EXPERIMENTAL NEUROLOGY, 2002, 178 (02) :301-305
[3]  
Boecker H, 1996, ACTA NEUROL SCAND, V93, P387
[4]   D2 receptors regulate dopamine transporter function via an extracellular signal-regulated kinases 1 and 2-dependent and phosphoinositide 3 kinase-independent mechanism [J].
Bolan, Elizabeth A. ;
Kivell, Bronwyn ;
Jaligam, Vanaja ;
Oz, Murat ;
Jayanthi, Lankupalle D. ;
Han, Yang ;
Sen, Namita ;
Urizar, Eneki ;
Gomes, Ivone ;
Devi, Lakshmi A. ;
Ramamoorthy, Sammanda ;
Javitch, Jonathan A. ;
Zapata, Agustin ;
Shippenberg, Toni S. .
MOLECULAR PHARMACOLOGY, 2007, 71 (05) :1222-1232
[5]   BIOENERGETIC AND OXIDATIVE STRESS IN NEURODEGENERATIVE DISEASES [J].
BOWLING, AC ;
BEAL, MF .
LIFE SCIENCES, 1995, 56 (14) :1151-1171
[6]   Stanley Fahn Lecture 2005:: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered [J].
Braak, Heiko ;
Bohl, Juergen R. ;
Muller, Christian M. ;
Rub, Udo ;
de Vos, Rob A. I. ;
Del Tredici, Kelly .
MOVEMENT DISORDERS, 2006, 21 (12) :2042-2051
[7]   Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct [J].
Conway, KA ;
Rochet, JC ;
Bieganski, RM ;
Lansbury, PT .
SCIENCE, 2001, 294 (5545) :1346-1349
[8]   Regional dopamine transporter gene expression in the substantia nigra from control and Parkinson's disease brains [J].
Counihan, TJ ;
Penney, JB .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1998, 65 (02) :164-169
[9]   Does levodopa slow or hasten the rate of progression of Parkinson's disease? [J].
Fahn, S .
JOURNAL OF NEUROLOGY, 2005, 252 (Suppl 4) :37-42
[10]  
Fahn S, 2004, NEW ENGL J MED, V351, P2498